TPTX News and Press, Turning Point Therapeutics Inc. From 05/12/20

Turning Point Therapeutics, Inc. (TPTX) Q1 2020 Earnings Conference Call May 12, 2020 4:30 p.m. ET Company Participants Jim Mazzola - SVP, Communication and IR Athena Countouriotis - President and CEO Yi Larson - EVP and CFO Conference Call Participants Corinne Jenkins - Go...

Turning Point Therapeutics (NASDAQ: TPTX ): Q1 GAAP EPS of -$1.69 misses by $1.03 . More news on: Turning Point Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Repotrectinib Granted Fast Track Designation in ROS1-Positive Advanced Non-Small Cell Lung Cancer Patients Not Previously Treated with a ROS1 Tyrosine Kinase Inhibitor  First Quarter Progress with Site Activations and Patient Enrollment Across Four Ongoing Clinical Trials in...

SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets o...

SAN DIEGO, April 16, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the publication of preclinical data and patient case studies from the Phase...

Turning Point Therapeutics (NASDAQ: TPTX ): Q4 GAAP EPS of -$0.58 beats by $0.07 . More news on: Turning Point Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Registrational Phase 2 TRIDENT-1 Study Continues Site Activation and Patient Enrollment   Preclinical Data Highlighting Repotrectinib Combinations and Additional Data for TPX-0131 to be Presented in Second Quarter, Given Rescheduling of American Association for Cancer Research...

SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Siegfried Reich, Ph.D. as executive vice president and ch...

SAN DIEGO, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a que...

SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson ...